Table 1 Clinical features of training and test sets in the fold 1
Clinical features | Number of patients | Training set (n = 2149) | Test set (n = 538) | p value |
|---|---|---|---|---|
Age | 2687 | 67.97 ± 9.65 | 67.87 ± 9.57 | 0.837 |
Sex | ||||
Male | 2005 (74.6%) | 1609 (80.2%) | 396 (19.8%) | 0.584 |
Female | 682 (25.4%) | 540 (79.2%) | 142 (20.8%) | |
Histology | ||||
Adenocarcinoma | 1501 (55.9%) | 1197 (79.7%) | 304 (20.3%) | 0.986 |
Squamous cell carcinoma | 1038 (1.5%) | 834 (80.3%) | 204 (19.7%) | |
Large cell carcinoma | 39 (1.5%) | 31 (79.5%) | 8 (20.5%) | |
NOS | 109 (4.1%) | 87 (79.8%) | 22 (20.2%) | |
Overall stage | ||||
I | 595 (22.1%) | 482 (81.0%) | 113 (19.0%) | 0.906 |
II | 269 (10.0%) | 213 (79.2%) | 56 (20.8%) | |
III | 836 (31.1%) | 667 (79.8%) | 169 (20.2%) | |
IV | 987 (36.7%) | 787 (79.7%) | 200 (20.3%) | |
T stage | ||||
T1 | 575 (21.4%) | 457 (79.5%) | 118 (20.5%) | 0.394 |
T2 | 1066 (39.7%) | 852 (79.9%) | 214 (20.1%) | |
T3 | 544 (20.2%) | 426 (78.3%) | 118 (21.7%) | |
T4 | 502 (18.7%) | 414 (82.5%) | 88 (175%) | |
N stage | ||||
N0 | 930 (34.6%) | 753 (81.0%) | 177 (19.0%) | 0.096 |
N1 | 329 (12.2%) | 273 (83.0%) | 56 (17.0%) | |
N2 | 709 (26.4%) | 546 (77.0%) | 163 (23.0%) | |
N3 | 719 (26.8%) | 577 (80.3%) | 142 (19.7%) | |
M stage | ||||
M0 | 1700 (69.3%) | 1363 (80.2%) | 337 (19.8%) | 0.773 |
M1 | 987 (36.7%) | 786 (79.6%) | 201 (20.4%) | |
Smoking history | ||||
Ever smoker | 1861 (69.3%) | 376 (20.2%) | 1485 (79.8%) | 0.763 |
Never smoker | 826 (30.7%) | 162 (19.6%) | 664 (80.4%) | |
Smoking amount | 2687 | 29.44 ± 27.28 | 29.12 ± 27.11 | 0.809 |
Dead status | ||||
Death | 1857 (69.1%) | 1485 (80.0%) | 372 (20.0%) | 0.974 |
Censored | 830 (30.9%) | 664 (80.0%) | 166 (20.0%) | |